Tag: Antibe therapeutics

June 6, 2019

VIDEO — US vs. Canada Healthcare Systems: Is One Better?

INN asked four company CEOs their thoughts on the US and Canadian healthcare systems and whether one is better than...
June 5, 2019

Antibe Therapeutics Reveals Lead Indication for ATB-352 Candidate

Dan Legault, CEO of Antibe Therapeutics, told INN that the company's second candidate, ATB-352, will be used to treat post-operative...
May 16, 2019

VIDEO Round-Up BBHIC 2019

BBHIC is over for another year. In case you missed it, here's a compilation of all INN's video interviews from...
May 9, 2019

VIDEO — Antibe Therapeutics CEO: Gearing Up to Be “Phase 3 Ready”

In this BBHIC interview, Antibe Therapeutics CEO Dan Legault says his company will be "Phase 3 ready" by the summer.
May 1, 2019

BBHIC 2019, Day 2: Notes From the Floor

The second day of the show had more company presentations, interviews and a panel discussion on R&D-stage healthcare companies.
April 24, 2019

Antibe Therapeutics Tackles Pain with Naproxen Derivative

The Investing News Network spoke with the CEO of Antibe Therapeutics about its lead drug candidate and how it is...
January 21, 2019

Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346

Antibe Therapeutics (TSXV:ATE,OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it has...